CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane

Positive
AI Analysis

Summary

GSK enters a $1 billion licensing deal with Suzhou-based SiranBio to develop siRNA therapeutics in the cardiometabolic and obesity space, expanding its partnership strategy with Chinese biotechs.

Importance:7/10
Sentiment:
0.60
licensing_dealsiRNAobesitycardiometabolicChina_partnershipGSK
Related Companies

Read the original article

Published by Endpoints News on May 6, 2026 1:39 PM

Read Original